文献速递免疫规划

江西省Sabin株脊髓灰质炎灭活疫苗与其他疫苗同时接种用于基础免疫和加强免疫的安全性及6个月免疫持久性

Safety and 6-month immune persistence of inactivated poliovirus vaccine (Sabin strains) simultaneously administrated with other vaccines for primary and booster immunization in Jiangxi Province, China.
PubMed 文献 · Vaccine · 2024-07-31

本研究在江西省纳入3200名婴幼儿,评价Sabin株脊髓灰质炎灭活疫苗(sIPV)单独或与其他疫苗同时接种用于基础免疫和加强免疫的安全性,并在末次接种后约6个月检测抗体持久性。结果显示sIPV安全性良好,基础免疫组与同时接种组不良反应发生率分别为3.19%和6.21%(P=0.001),加强免疫组间无显著差异;甲肝、麻疹、腮腺炎和风疹抗体未受同时接种干扰,但百日咳抗体血清阳性率低于30%,提示需加强接种。

要点

  • sIPV基础免疫同时接种DTaP的不良反应发生率为6.21%,高于单独接种组的3.19%(P=0.001)。
  • 加强免疫时sIPV单独接种与同时接种其他疫苗的不良反应发生率无显著差异(2.25% vs 2.50%,P=0.788)。
  • 加强免疫后三种脊灰病毒抗体血清阳性率均为100%,但百日咳抗体血清阳性率低于30%。

核心结论

  • sIPV无论单独接种还是同时接种其他疫苗,用于基础免疫和加强免疫均显示出良好的安全性和免疫持久性。
  • 甲肝、麻疹、腮腺炎和风疹抗体未受同时接种干扰。
  • 百日咳抗体血清阳性率和几何平均浓度提示需要加强接种。

研究设计与样本

  • 研究共招募3200名婴幼儿,其中2000名2-3月龄婴儿按1:1随机分为sIPV基础免疫组和sIPV+DTaP组进行基础免疫。
  • 另1200名18月龄及以上儿童按2:2:1:1随机分为sIPV加强组、sIPV+甲肝灭活疫苗组、sIPV+麻腮风疫苗组和sIPV+甲肝减毒活疫苗组进行加强免疫。
  • 所有参与者每次接种后30天内由监护人通过微信小程序自我报告不良事件。
  • 末次接种后5-7个月采集约200份血样检测脊灰病毒和其他病毒抗体。

主要发现

  • 安全性研究共纳入3198名参与者,包括1999名2-3月龄婴儿和1199名18-26月龄儿童。
  • 基础免疫中,sIPV基础免疫组和sIPV+DTaP组的不良反应发生率分别为3.19%和6.21%(P=0.001)。
  • 加强免疫中,sIPV加强组的不良反应发生率为2.25%,sIPV+其他疫苗组总计为2.50%(P=0.788)。
  • 大多数不良反应为轻度,发热是所有组中最常见的症状,未观察到疫苗相关严重不良事件。
  • 基础免疫后,sIPV基础免疫组和sIPV+DTaP组对1型脊灰病毒抗体血清阳性率分别为92.31%和100%(P=0.031);对2型分别为96.15%和98.57%(P=0.575);对3型分别为98.08%和91.43%(P=0.237)。

关键数值与推荐

  • 基础免疫组不良反应发生率:sIPV基础免疫组3.19% vs sIPV+DTaP组6.21%(P=0.001)。
  • 加强免疫组不良反应发生率:sIPV加强组2.25% vs sIPV+其他疫苗组总计2.50%(P=0.788)。
  • 基础免疫后1型脊灰抗体血清阳性率:sIPV基础免疫组92.31% vs sIPV+DTaP组100%(P=0.031)。
  • 基础免疫后2型脊灰抗体血清阳性率:sIPV基础免疫组96.15% vs sIPV+DTaP组98.57%(P=0.575)。
  • 基础免疫后3型脊灰抗体血清阳性率:sIPV基础免疫组98.08% vs sIPV+DTaP组91.43%(P=0.237)。

临床怎么用

  • sIPV可用于基础免疫和加强免疫,单独接种或与其他疫苗同时接种均显示出良好安全性。
  • 同时接种甲肝、麻疹、腮腺炎和风疹疫苗未干扰抗体应答。
  • 百日咳抗体血清阳性率低,作者认为需加强接种。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: This study aims to evaluate the safety of a new inactivated poliomyelitis vaccine (Sabin strains) (sIPV) for large-scale use in primary and booster immunizations, whether simultaneously administered with other vaccines or not and to explore the persistence of all vaccines at approximately six months after vaccination. METHOD: A total of 3200 infants were recruited into this study, including 2000 infants aged 2-3 months randomly assigned (1:1) into the "sIPV basic" or the "sIPV+DTaP" group for primary immunization of sIPV. Another 1200 children aged 18 months old and above were randomly assigned (2:2:1:1) into the "sIPV booster," "sIPV+HepA-I," "sIPV+MMR", or "sIPV+HepA-L" group for booster immunization of sIPV. Adverse events within 30 days of each vaccination dose in all participants were self-reported by guardians using a WeChat mini-program. Approximately 200 blood samples were collected at 5-7 months after the final vaccination to test for antibodies against poliovirus and other viruses. RESULTS: 3198 participants in total were included in the safety study, including 1999 infants aged 2-3 months old and 1199 children aged 18-26 months old. For primary immunization, the incidence of adverse reactions in the "sIPV basic" and the "sIPV+DTaP" group were 3.19 and 6.21% (P = 0.001), respectively. For booster immunization, the incidences of adverse reaction for the "sIPV booster" group were 2.25%, while the incidence for the "sIPV +others" group in total was 2.50% (P = 0.788). Most adverse reactions were mild. Fever was the most common symptom in all groups. No vaccine-related serious adverse events (SAEs) were observed in this study. The seropositivity rates of antibodies in the "sIPV basic" and the "sIPV+DTaP" group were 92.31 and 100% against type 1 poliovirus (P = 0.031); 96.15% and 98.57% against type 2 poliovirus (P = 0.575); 98.08% and 91.43% against type 3 poliovirus (P = 0.237), respectively. Regarding booster vaccination with sIPV, whether co-administered with other vaccines or not, the seropositivity rates of antibodies against the three types of polioviruses were all 100%. Seropositivity rates of antibodies against hepatitis A, measles, mumps, and rubella were all no <77%, except for pertussis, which was <30%. CONCLUSION: sIPV demonstrated good safety and immune persistence for primary and booster vaccinations, whether administered singly or simultaneously. Antibodies against hepatitis A, measles, mumps and rubella were not disrupted by the co-vaccination. However, the seropositivity rates and geometric mean concentrations (GMCs) of antibodies against pertussis indicate the necessity for a booster dose.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Guo S, Li Z, Zheng M, et al. Safety and 6-month immune persistence of inactivated poliovirus vaccine (Sabin strains) simultaneously administrated with other vaccines for primary and booster immunization in Jiangxi Province, China. Vaccine. 2024. PMID: 39088987. doi:10.1016/j.vaccine.2024.126183

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。